Footnotes

NATIONAL HEALTH AMENDMENT (PHARMACEUTICAL BENEFITS SCHEME) BILL 2010 [PROVISIONS]

[1]        Community Affairs Legislation Committee, National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010 [Provisions] Report, 26 August 2010, p. 1.

[2]        Department of Health and Ageing (DoHA), What is the PBS?, available: http://www.pbs.gov.au/html/consumer/pbs/about (accessed 2 May 2010). 

[3]        DoHA, New PBS Safety Net thresholds, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-safetynet-changes (accessed 6 May 2010).

[4]         DoHA, Submission 31, p. 4. 

[5]         DoHA, Submission 31, p. 4. 

[6]         DoHA, Submission 31, p. 4. 

[7]        DoHA, Pharmaceutical Benefits Advisory Committee, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-listing-committee3.htm (accessed 3 November 2010). 

[8]        DoHA, Pharmaceutical Benefits Advisory Committee, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-listing-committee3.htm (accessed 3 November 2010). 

[9]        DoHA, Submission 31, p. 6. 

[10]      DoHA, Fact Sheet: Pharmaceutical Benefits Scheme (PBS) Reform, 2 February 2007, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/24693658DD49E286CA2572750081DB74/$File/PBS%20Reform%202Feb07.pdf (accessed 4 August 2010). 

[11]      Senate Standing Committee on Community Affairs, National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007 [Provisions] Report, June 2007, p. 2. 

[12]      National Health Act 1953, s. 99ACJ.

[13]      Senate Standing Committee on Community Affairs, National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2007 [Provisions] Report, June 2007, p. 2. 

[14]      DoHA, Price disclosure requirements, available: http://www.pbs.gov.au/html/industry/static/pricing_matters/price_disclosure/price_disclosure_requirements (accessed 4 August 2010). 

[15]      DoHA, Price disclosure requirements, available: http://www.pbs.gov.au/html/industry/static/pricing_matters/price_disclosure/price_disclosure_requirements (accessed 4 August 2010) & National Health Act 1953, s. 99ADA(2). 

[16]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 1.

[17]      That is, the Commonwealth undertook not to introduce any measure which favours the prescribing or dispensing of generic brands of a drug over originator brands of the same drug where the approved price to pharmacists is the same.

[18]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 1.

[19]      The Hon Nicola Roxon, Minister for Health and Ageing, Second reading speech, 2 June 2010, p. 4897.

[20]      ParlInfo, National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, available: http://parlinfo.aph.gov.au/parlInfo/search/display/display.w3p;query=Id%3A%22legislation%2Fbillhome%2Fr4385%22 (accessed 13 September 2010).

[21]      The Hon Nicola Roxon, Minister for Health and Ageing, Second reading speech, 29 September 2010, pp 80 & 82.

[22]      Explanatory Memorandum, p. 1.

[23]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, clause 99ACA(2)(a).

[24]      Explanatory Memorandum, p. 1 & National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, schedule 2.

[25]      Explanatory Memorandum, p. 1.

[26]      DoHA, Fact sheet: Pharmaceutical Benefits Scheme (PBS) Reform, 2 February 2007, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/24693658DD49E286CA2572750081DB74/$File/PBS%20Reform%202Feb07.pdf (accessed 15 July 2010).

[27]      Explanatory Memorandum, p. 1.

[28]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, schedule 3.

[29]      Explanatory Memorandum, p. 17.

[30]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, clause 85AC.

[31]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, commencement.

[32]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, clause 99ADJ.

[33]      Explanatory Memorandum, p. 2. 

[34]      DoHA, New PBS Safety Net thresholds, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-safetynet-changes (accessed 6 May 2010).

[35]      National Health Act 1953, s. 84. 

[36]      A "pharmaceutical benefit" is a drug or medicinal preparation listed on the PBS.

[37]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, clause 98AC(4).

[38]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, commencement. 

[39]      Explanatory Memorandum, p. 2.

[40]      Section 100 of the National Health Act 1953 provides for alternative ways of providing medicines where supply through community pharmacies is unsuitable (reasons might include the cost of storage, requirements for particular controls over dispensing, the need for medical supervision or administration during treatment). These medicines, however, must still meet the government's criteria for clinical and cost-effectiveness.

[41]      A "pharmaceutical item" is a particular form and strength of a drug or medicinal preparation listed on the PBS.

[42]      A "listed drug" is a drug or medicinal preparation listed on the PBS for the purposes of allocating that drug or medicinal preparation to a formulary, and / or to a therapeutic group. 

[43]      Explanatory Memorandum, p. 37. 

[44]      Explanatory Memorandum, p. 37. 

[45]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 2.

[46]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, schedule 1.

[47]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 2.

[48]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 2.

[49]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, schedule 2.

[50]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 2.

[51]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 2.

[52]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 3.

[53]      National Health Amendment (Pharmaceutical Benefits Scheme) Bill 2010, clause 99ADJ. 

[54]      Generic Medicines Industry Association (GMiA), Submission 8, p. 15. 

[55]      See Sigma Pharmaceuticals, Submission 12, p. 1 & Hospira, Submission 20, p. 3. 

[56]      GMiA, Submission 8, p. 15. 

[57]      Ms Carol Bennett, Executive Director, Consumers Health Forum (CHF), Proof Committee Hansard, 9 November 2010, p. 32. 

[58]      Mr David Learmonth, Deputy Secretary, DoHA, Proof Committee Hansard, 9 November 2010, pp 46-47 & 51. 

[59]      Mr David Learmonth, Deputy Secretary, DoHA, Proof Committee Hansard, 9 November 2010, p. 51. 

[60]      Mr David Learmonth, Deputy Secretary, DoHA, Proof Committee Hansard, 9 November 2010, pp 53-54. 

[61]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Proof Committee Hansard, 9 November 2010, p. 24. 

[62]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Proof Committee Hansard, 9 November 2010, p. 26. 

[63]      Ms Kate Lynch, Chief Executive Officer, GMiA, Proof Committee Hansard, 9 November 2010, p. 3. 

[64]      Ms Kate Lynch, Chief Executive Officer, GMiA, Proof Committee Hansard, 9 November 2010, p. 3. 

[65]      Ms Kate Lynch, Chief Executive Officer, GMiA, Proof Committee Hansard, 9 November 2010, p. 4. 

[66]      Ms Kate Lynch, Chief Executive Officer, GMiA, Proof Committee Hansard, 9 November 2010, p. 4. 

[67]      Ms Kate Lynch, Chief Executive Officer, GMiA, Proof Committee Hansard, 9 November 2010, p. 4. 

[68]      Dr Martin Cross, Chairman, GMiA and Managing Director, Alphapharm Pty Ltd, Proof Committee Hansard, 9 November 2010, p. 4. 

[69]      Mr David Learmonth, Deputy Secretary, DoHA, Proof Committee Hansard, 9 November 2010, p. 51. 

[70]      Dr Martin Cross, Chairman, GMiA and Managing Director, Alphapharm Pty Ltd, Proof Committee Hansard, 9 November 2010, p. 5. 

[71]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Proof Committee Hansard, 9 November 2010, p. 23. 

[72]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Proof Committee Hansard, 9 November 2010, p. 22. 

[73]      Dr Martin Cross, Chairman, GMiA and Managing Director, Alphapharm Pty Ltd, Proof Committee Hansard, 9 November 2010, p. 5. 

[74]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Proof Committee Hansard, 9 November 2010, p. 22. 

[75]      Mr David Learmonth, Deputy Secretary, DoHA, Proof Committee Hansard, 9 November 2010, pp 47-48. 

[76]      Mr David Learmonth, Deputy Secretary, DoHA, Proof Committee Hansard, 9 November 2010, p. 48.

[77]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Proof Committee Hansard, 9 November 2010, p. 47. 

[78]      Mr David Learmonth, Deputy Secretary, Department of Health and Ageing, Proof Committee Hansard, 9 November 2010, p. 48. 

[79]      DoHA, Answers to questions on notice, 9 November 2010 (received 12 November 2010). 

[80]      See National Pharmaceutical Services Association (NPSA), Submission 3, p. 7; Ms Toni Riley, Chair, Health Economics Committee, The Pharmacy Guild of Australia, Proof Committee Hansard, 9 November 2010, p. 15 & Dr Martin Cross, Chairman, GMiA and Managing Director, Alphapharm Pty Ltd, Proof Committee Hansard, 9 November 2010, p. 2. 

[81]      Mr Patrick Davies, President, NPSA and Chief Executive Officer, Symbion Pharmacy Services, Proof Committee Hansard, 9 November 2010, p. 38. 

[82]      NPSA, Submission 3, p. 7. 

[83]      Mr Patrick Davies, President, NPSA and Chief Executive Officer, Symbion Pharmacy Services, Proof Committee Hansard, 9 November 2010, p. 40. 

[84]      Ms Toni Riley, Chair, Health Economics Committee, The Pharmacy Guild of Australia, Proof Committee Hansard, 9 November 2010, p. 12. 

[85]      Ms Toni Riley, Chair, Health Economics Committee, The Pharmacy Guild of Australia, Proof Committee Hansard, 9 November 2010, p. 15. 

[86]      Dr Martin Cross, Chairman, GMiA and Managing Director, Alphapharm Pty Ltd, Proof Committee Hansard, 9 November 2010, p. 2. 

[87]      DoHA, Answers to questions on notice, 9 November 2010 (received 12 November 2010). 

[88]      The Pharmacy Guild of Australia, Submission 4, pp 2 & 5. 

[89]      Ms Toni Riley, Chair, Health Economics Committee, The Pharmacy Guild of Australia, Proof Committee Hansard, 9 November 2010, pp 11-12. 

[90]      The Pharmacy Guild of Australia, Answers to questions on notice, 9 November 2010 (received 11 November 2010). 

[91]      The Pharmacy Guild of Australia, Supplementary Submission, p. 2. 

[92]      The Pharmacy Guild of Australia, Supplementary Submission, p. 2. 

[93]      Mr Patrick Davies, President, NPSA and Chief Executive Officer, Symbion Pharmacy Services, Proof Committee Hansard, 9 November 2010, p. 44. 

[94]      DoHA, Answers to questions on notice, 9 November 2010 (received 12 November 2010). 

[95]      DoHA, Submission 31, p. 4. 

[96]      The Treasury, Australia to 2050: Future Challenges, available: http://www.treasury.gov.au/igr/igr2010/report/pdf/IGR_2010.pdf (accessed 15 November 2010), p. 54.

[97]      DoHA, Submission 31, p. 11.

[98]      DoHA, Submission 31, p. 5. 

[99]      DoHA, Submission 31, p. 10. 

[100]    DoHA, Submission 31, pp 12-13. 

[101]    DoHA, Submission 31, p. 3. 

[102]    DoHA, Submission 31, p. 20. 

[103]    DoHA, Submission 31, p. 20. 

[104]    DoHA, Submission 31, p. 20. 

[105]    DoHA, Submission 31, p. 3.